Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Ultra high power (100  kW) fiber laser welding of steel.

Kawahito Y, Wang H, Katayama S, Sumimori D.

Opt Lett. 2018 Oct 1;43(19):4667-4670. doi: 10.1364/OL.43.004667.

PMID:
30272710
2.

DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.

Nariai T, Fujita K, Kawane K, Mori M, Nakayama R, Matsuda K, Katayama S, Fukuda N, Hori S, Iwata M, Hasegawa F, Suzuki K, Kato H.

J Pharmacol Exp Ther. 2015 Jul;354(1):2-9. doi: 10.1124/jpet.114.221341. Epub 2015 Apr 28.

PMID:
25922341
3.

[Association of clinical symptom between schizophrenia and exploratory eye movement].

Takahashi S, Suzuki M, Matsushima E, Ohta K, Kurachi M, Hayashi T, Morita K, Maeda H, Katayama S, Hirayasu Y, Okubo Y, Uchiyama M, Kojima T.

Seishin Shinkeigaku Zasshi. 2013;115(1):3-9. Japanese. No abstract available.

PMID:
23991469
4.

Relationships between exploratory eye movement dysfunction and clinical symptoms in schizophrenia.

Suzuki M, Takahashi S, Matsushima E, Tsunoda M, Kurachi M, Okada T, Hayashi T, Ishii Y, Morita K, Maeda H, Katayama S, Otsuka T, Hirayasu Y, Sekine M, Okubo Y, Motoshita M, Ohta K, Uchiyama M, Kojima T.

Psychiatry Clin Neurosci. 2012 Apr;66(3):187-94. doi: 10.1111/j.1440-1819.2011.02314.x. Epub 2012 Feb 28.

5.

Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.

Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K.

Pharmacology. 2012;89(1-2):44-52. doi: 10.1159/000335559. Epub 2012 Feb 1.

PMID:
22302095
6.

SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats.

Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K.

J Cardiovasc Pharmacol. 2012 May;59(5):458-64. doi: 10.1097/FJC.0b013e3182495543.

PMID:
22240917
7.

SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.

Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K.

J Pharmacol Sci. 2011;115(3):346-53. Epub 2011 Feb 24.

8.

Exploratory eye movement dysfunction as a discriminator for schizophrenia : a large sample study using a newly developed digital computerized system.

Suzuki M, Takahashi S, Matsushima E, Tsunoda M, Kurachi M, Okada T, Hayashi T, Ishii Y, Morita K, Maeda H, Katayama S, Kawahara R, Otsuka T, Hirayasu Y, Sekine M, Okubo Y, Motoshita M, Ohta K, Uchiyama M, Kojima T.

Eur Arch Psychiatry Clin Neurosci. 2009 Apr;259(3):186-94. doi: 10.1007/s00406-008-0850-7. Epub 2009 Jan 22.

PMID:
19165524
9.

A study of the calcium complex of a glucosylceramide, soya-cerebroside II.

Kurosu M, Katayama S, Shibuya H, Kitagawa I.

Chem Pharm Bull (Tokyo). 2007 Dec;55(12):1758-61.

10.

Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats.

Shirayama Y, Yamamoto A, Nishimura T, Katayama S, Kawahara R.

Eur Neuropsychopharmacol. 2007 Sep;17(9):616-26. Epub 2007 Apr 30.

PMID:
17467960
11.

Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor.

Ishida H, Shirayama Y, Iwata M, Katayama S, Yamamoto A, Kawahara R, Nakagome K.

Hippocampus. 2007;17(4):271-80.

PMID:
17265460
12.

Postoperative adjuvant treatment for pineal parenchymal tumour of intermediate differentiation.

Anan M, Ishii K, Nakamura T, Yamashita M, Katayama S, Sainoo M, Nagatomi H, Kobayashi H.

J Clin Neurosci. 2006 Nov;13(9):965-8. Epub 2006 Aug 14.

PMID:
16904896
13.

Tricyclic quinoxalinediones, aza-kynurenic acids, and indole-2-carboxylic acids as in vivo active NMDA-glycine antagonists.

Nagata R, Katayama S, Ohtani K, Tanaka H, Shimago K.

Curr Top Med Chem. 2006;6(7):733-45. Review.

PMID:
16719813
14.

[A deficit in preattentive processing of visual information in schizophrenic patients].

Kojima K, Katayama S, Takaki M, Yoshioka S, Kawahara R.

Seishin Shinkeigaku Zasshi. 2005;107(3):235-47. Japanese.

PMID:
15856747
15.

Tricyclic indole-2-carboxylic acids: highly in vivo active and selective antagonists for the glycine binding site of the NMDA receptor.

Katayama S, Ae N, Kodo T, Masumoto S, Hourai S, Tamamura C, Tanaka H, Nagata R.

J Med Chem. 2003 Feb 27;46(5):691-701.

PMID:
12593650
16.

[Sleep-related epilepsy].

Katayama S, Yoshioka S, Kawahara R.

Ryoikibetsu Shokogun Shirizu. 2002;(37 Pt 6):303-5. Review. Japanese. No abstract available.

PMID:
12483887
17.

Relationships between serum magnesium levels and clinical background factors in patients with mood disorders.

Imada Y, Yoshioka S, Ueda T, Katayama S, Kuno Y, Kawahara R.

Psychiatry Clin Neurosci. 2002 Oct;56(5):509-14.

Supplemental Content

Loading ...
Support Center